ArticleCancer research2017
PD-1 Status in CD8
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 3 pooled it
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
169 citing papers in PubMed, 3 syntheses or guidelines pooled it, 247 citations in OpenAlex.
- Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2022Pooled it
- Pooled it
- Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis.Aging · 2019Pooled it
- Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma.CNS neuroscience & therapeutics · 2025Trial
- Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study.Cancer research communications · 2025Trial
- Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Journal for immunotherapy of cancer · 2024Trial
- Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.Cancer research communications · 2022Trial
- CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2020Trial
- PD-L1 Mediates Dysfunction in Activated PD-1Cancer immunology research · 2018Trial
- IL-1α Expands SLC2A1highSPP1highIFNlow Myeloid Cells to Drive Immune Escape and Malignant Transformation of Precancers.Cancer research · 2026Article
- ULK1-dependent autophagy initiation promotes MHC-I degradation and immune evasion in HPV-positive head and neck cancer.Cancer immunology research · 2026Article
- Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid Leukemia.Research square · 2026Article
- PD-1Biomarker research · 2026Article
- Review
- Chemotherapeutic efficacy of nano formulation capecitabine@SNPs and gamma radiation: a novel metronomic approach for breast cancer treatment.Drug delivery and translational research · 2026Article
- Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.Biomarker research · 2026Review
- IL-2 Free Expansion of T Cells with Immunofilaments.Advanced healthcare materials · 2026Article
- Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
109 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Benjamin A KansyDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Fernando Concha-BenaventeDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Raghvendra M SrivastavaDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Hyun-Bae JieDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Gulidanna ShayanSchool of Medicine, Tsinghua University, Beijing, China.
Yu LeiDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, Michigan.
Jessica MoskovitzDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jennifer MoyDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Jing LiSchool of Medicine, Tsinghua University, Beijing, China.
Sven BrandauDepartment of Otorhinolaryngology, University Hospital Essen, Germany.
Stephan LangDepartment of Otorhinolaryngology, University Hospital Essen, Germany.
Nicole C SchmittDepartment of Otolaryngology, Johns Hopkins University, Baltimore, Maryland, and National Institute on Deafness and Communication Disorders, National Institutes of Health, Bethesda, Maryland.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
William E GoodingBiostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
David A ClumpDepartment of Radiation Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Robert L FerrisDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania. ferrrl@upmc.edu.
Tsinghua University · CNDana-Farber Cancer Institute · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6MMechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytesR01CA206517 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert L. Ferris, Lawrence P. Kane · 2016 to 2026
$4.6MMechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell CarcinomaZIADC000090 · NIDCD · NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS · PI SCHMITT, NICOLE · 2016 to 2020
$3.9MPostdoctoral Training in Head and Neck OncologyT32CA060397 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZEVALLOS, JOSE P. · 1994 to 2024
$2.7MImmune activation by cetuximab in head and neck cancer patientsR01DE019727 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FERRIS, ROBERT L. · 2010 to 2014
$2.0MAutophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximabR00DE024173 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEI, YU LEO · 2016 to 2018
$863kAutophagy-promoting NLRX1-TUFM complex and cancer cell resistance to cetuximabK99DE024173 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEI, YU LEO · 2014 to 2015
$254kNCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA206517NCI NIH HHS T32 CA060397NIDCR NIH HHS K99 DE024173NIDCR NIH HHS R00 DE024173NIDCR NIH HHS R01 DE019727
Abstract
Improved understanding of expression of immune checkpoint receptors (ICR) on tumor-infiltrating lymphocytes (TIL) may facilitate more effective immunotherapy in head and neck cancer (HNC) patients. A higher frequency of PD-1
Indexed as
AnimalsAntibodies, MonoclonalCD8-Positive T-LymphocytesCells, CulturedDisease-Free SurvivalDisease Models, AnimalGene ExpressionHead and Neck NeoplasmsHumansInterferon-gammaLymphocytes, Tumor-InfiltratingMice, Inbred C57BLOutcome Assessment, Health CarePapillomavirus InfectionsPrognosisProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalInterferon-gammaPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.